On the latest episode of The BioCentury Show, Editor in Chief Simone Fishburn speaks with Bahija Jallal, CEO of Immunocore and the former president of Medimmune. While some biotechs are circumspect about gathering data during clinical trials that might not support the product in question, Jallal sees it as part of the obligation to patients and the field to learn as much as possible, as efficiently as possible. And that strategy has informed how the company will take its TCR technology into earlier lines of treatment and new indications.

View full story: https://www.biocentury.com/article/655504

#biopharma #pharma #biotech #lifescience #RandD #DrugDevelopment #CEO

00:00 - Introduction
04:18 - Getting a New Modality to Market
17:15 - Infectious Pipeline
22:04 - Autoimmune Pipeline
27:24 - Leading in Challenging Times